New pill could replace needles for anemia in dialysis patients
NCT ID NCT07300111
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new pill called daprodustat against a standard injectable drug (darbepoetin alfa) for treating anemia in people on hemodialysis. About 100 Chinese adults will take either the pill daily or the injection weekly for 28 weeks. The goal is to see if the pill works just as well at raising hemoglobin levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daprodustat (a pill that stimulates red blood cell production)
What this could lead to
If successful, daprodustat could offer a convenient once-daily pill option to manage anemia in dialysis patients, potentially replacing injectable treatments.
What could go wrong
This is a non-inferiority trial, so it may only show that daprodustat is as good as, not better than, existing therapy. It is also limited to Chinese patients on hemodialysis, so results may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••